NCT06560489View on ClinicalTrials.gov

Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

January 20, 2025

Study Completion Date

May 20, 2025

Conditions
Hiv
Interventions
DRUG

Subjects will be randomly assigned to receive 1.25 mg, 2.5 mg, 5 mg, or 10 mg of LP-98.

This study consisted of 4 cohorts with 10 subjects in each group, who were randomly assigned to receive LP-98 treatment of 1.25 mg, 2.5 mg, 5 mg, and 10 mg. The method of administration was subcutaneous injection, and the interval of administration was 14 days, a total of 4 doses.

Trial Locations (1)

Unknown

Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital), Zhengzhou

All Listed Sponsors
collaborator

Chinese Academy of Medical Sciences

OTHER

lead

Shanxi Kangbao Biological Product Co., Ltd.

INDUSTRY